Advertisement
Advertisement

COLL

COLL logo

Collegium Pharmaceutical, Inc. Common Stock

47.68
USD
Sponsored
+0.76
+1.61%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

47.67

-0.01
-0.01%

COLL Earnings Reports

Positive Surprise Ratio

COLL beat 19 of 40 last estimates.

48%

Next Report

Date of Next Report
Feb 19, 2026
Estimate for Q4 25 (Revenue/ EPS)
$210.29M
/
$2.37
Implied change from Q3 25 (Revenue/ EPS)
+0.44%
/
+5.33%
Implied change from Q4 24 (Revenue/ EPS)
+15.57%
/
+33.90%

Collegium Pharmaceutical, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, COLL reported earnings of 2.25 USD per share (EPS) for Q3 25, beating the estimate of 2.08 USD, resulting in a 7.92% surprise. Revenue reached 209.36 million, compared to an expected 192.90 million, with a 8.53% difference. The market reacted with a +13.42% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of 2.37 USD, with revenue projected to reach 210.29 million USD, implying an increase of 5.33% EPS, and increase of 0.44% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Collegium Pharmaceutical, Inc. Common Stock reported EPS of $2.25, beating estimates by 7.92%, and revenue of $209.36M, 8.53% above expectations.
The stock price moved up 13.42%, changed from $35.85 before the earnings release to $40.66 the day after.
The next earning report is scheduled for Feb 19, 2026.
Based on 8 analysts, Collegium Pharmaceutical, Inc. Common Stock is expected to report EPS of $2.37 and revenue of $210.29M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement